Latest Omeros Corporation Stories
-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE, March 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER)
-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE, Feb.
-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses -- SEATTLE, Feb.
-- Enrollment in Huntington's Phase 2 Trial Expected Soon -- SEATTLE, Feb. 5, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S.
-- Phase 2 Program Expected to Initiate this Quarter -- SEATTLE, Feb.
- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE, Jan.
- An armed gangster.